Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102426 · ClinicalTrials.gov registry record · Phase 3
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
A Phase 3 study of Relapsed/Refractory Multiple Myeloma, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 3
- Development phase
- 255
- Enrollment target
- 20
- Study locations
NCT01102426 is a Phase 3 study of Relapsed/Refractory Multiple Myeloma that has completed, run by PharmaMar. The registered enrollment target is 255 participants, above the 152-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT01102426, a Phase 3 study of Relapsed/Refractory Multiple Myeloma, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 255 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Plitidepsin
Study Locations (20)
Other
- 108 - Adelaide
- 102 - Canberra
- 101 - Geelong
- 105 - Parkville
- 106 - Perth
- 104 - South Brisbane
- 109 - Woodville
- 202 - Graz
- 204 - Innsbruck
- 203 - Salzburg
- 201 - Vienna
- 205 - Vienna
- 208 - Vienna
- 304 - Bruges
- 301 - Brussels
Alabama
- 1107 - Tuscaloosa
California
- 1103 - Los Angeles
Florida
- 1105 - Jacksonville
New York
- 1102 - New York
Ohio
- 1104 - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01102426
The ClinicalTrials.gov registry entry for NCT01102426 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 152-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (68% higher). The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01102426 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01102426 about?
NCT01102426 is a clinical study titled "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma". Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.
What is the current status of trial NCT01102426?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2010-06. Estimated completion is 2017-11.
What conditions does trial NCT01102426 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT01102426?
The interventions under investigation include: Dexamethasone (DRUG), Plitidepsin (DRUG).
Who is sponsoring clinical trial NCT01102426?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01102426 being conducted?
This trial has 20 study locations across Alabama, California, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
COMPLETED · Phase 3
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.